Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Collplant Holdings ( (CLGN) ) just unveiled an announcement.
On May 29, 2025, CollPlant Biotechnologies Ltd. announced a securities purchase agreement with institutional investors, involving the sale of 1,200,002 ordinary shares and accompanying warrants, expected to raise approximately $3.6 million. The funds will support corporate purposes, including collaboration with AbbVie on a dermal filler product. The offering is set to close on June 2, 2025, with implications for the company’s financial strategy and market positioning.
The most recent analyst rating on (CLGN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.
Spark’s Take on CLGN Stock
According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.
The overall score of 47 reflects significant financial performance challenges as the primary concern, with ongoing revenue and cash flow issues. Technical analysis suggests some potential for price stabilization, but valuation metrics are weak due to negative earnings. The earnings call provided some optimism with strategic advancements, but the financial strain remains a substantial risk.
To see Spark’s full report on CLGN stock, click here.
More about Collplant Holdings
CollPlant Biotechnologies Ltd. operates in the biotechnology industry, focusing on regenerative medicine. The company is known for its development of innovative products such as dermal fillers, leveraging its expertise in plant-based collagen and tissue engineering technologies.
Average Trading Volume: 61,422
Technical Sentiment Signal: Sell
Current Market Cap: $36.43M
For detailed information about CLGN stock, go to TipRanks’ Stock Analysis page.